.jpeg)
2026-09-14 03:25:01
Bosutinib is used for Ph+ chronic myeloid leukemia. Symptom change in a few days does not reflect efficacy. Response is tracked by CBC, BCR-ABL quantification, and cytogenetics; molecular remission often takes months, with mutation retesting for T315I/V299L.
2026-09-14 03:20:04
Bedaquiline is used only in combination for drug-resistant tuberculosis. The classic course is about 24 weeks, while all-oral regimens may run 6 or 9 months; complex resistance can be extended after specialist review based on cultures, susceptibility, and safety.
2026-09-14 03:16:19
Acalabrutinib is usually 100mg twice daily for CLL/SLL monotherapy or with obinutuzumab, and for transplant-ineligible newly diagnosed MCL with bendamustine plus rituximab. This guide simplifies dosing, toxicity breaks, and interactions.
2026-09-14 03:09:28
Enzalutamide commonly causes fatigue, musculoskeletal pain, dizziness, and hot flashes, with attention also needed for hypertension, falls, fractures, seizure, PRES, and ischemic heart disease. This guide covers tiered management and red-flag symptoms.
2026-09-14 03:06:37
Bosutinib is a BCR-ABL and Src-family tyrosine kinase inhibitor for newly diagnosed and resistant/intolerant Philadelphia chromosome-positive chronic myeloid leukemia, covering chronic, accelerated, blast phases and pediatric chronic-phase use.
2026-09-10 03:33:16
Tamoxifen is a long-established endocrine therapy for breast cancer. Long-term use requires awareness of venous thromboembolism and endometrial abnormalities. This article outlines key adverse effects and at-risk populations.
2026-09-10 03:00:52
Worsening symptoms or declining cardiac function during acoramidis treatment for ATTR-CM should not be directly labeled as drug resistance. This article explains the mechanism, proper assessment methods, and dosing compliance.
2026-09-10 02:56:36
Lorlatinib has only one formal contraindication (prohibited co-administration with strong CYP3A inducers), but six major safety risks require close attention, including CNS effects, dyslipidemia, and interstitial lung disease.
2026-09-10 02:52:45
A multicenter Ib/II trial shows the azacitidine + venetoclax + ivosidenib triplet regimen achieves 95% ORR in newly diagnosed IDH1-mutant AML with manageable safety.
2026-09-09 07:04:37
Dacomitinib is a second-generation irreversible EGFR TKI for first-line treatment of metastatic NSCLC with EGFR exon 19 deletion or L858R mutation. This article details dosing, switching strategies, comparison with osimertinib, and adverse event management.
2026-09-09 06:37:44
Abemaciclib is a CDK4/6 inhibitor for hormone receptor-positive, HER2-negative breast cancer. This article explains its mechanism, synergy with endocrine therapy, efficacy differences between mono and combination, and precautions when switching from other CDK4/6 inhibitors.
2026-09-08 06:24:42
Fezolinetant is a non-hormonal oral medication for moderate to severe vasomotor symptoms of menopause. This article details standard dosing, missed dose management, and liver function monitoring.
